The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumours

Gynecologic Oncology

Volumn 133, Issue 2, 2014, Pages 382-387

  Rosario, Roseanne ^a   Cohen, Paul A ^b   Shelling, Andrew N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

FOXL2; Granulosa cell tumours

Indexed keywords

IMATINIB; PACLITAXEL; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXL2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT DISEASE; ALLELE; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; GENE FUNCTION; GRANULOSA CELL TUMOR; HUMAN; MEDLINE; MUTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR DIAGNOSIS; TUMOR GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

FOXL2; GRANULOSA CELL TUMOURS;

ADULT; APOPTOSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANULOSA CELL TUMOR; HUMANS; MUTATION; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899653573     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.12.012     Document Type: Review

References (71)

1. N. Colombo, G. Parma, V. Zanagnolo, and A. Insinga Management of ovarian stromal cell tumors J Clin Oncol 25 2007 2944 2951
2. P.J. Fuller, S. Chu, S. Fikret, and H.G. Burger Molecular pathogenesis of granulosa cell tumours Mol Cell Endocrinol 191 2002 89 96
3. E.A. Boyce, I. Costaggini, A. Vitonis, C. Feltmate, M. Muto, and R. Berkowitz et al. The epidemiology of ovarian granulosa cell tumors: a case-control study Gynecol Oncol 115 2009 221 225
4. B.E. Miller, B.A. Barron, J.Y. Wan, J.E. Delmore, E.G. Silva, and D.M. Gershenson Prognostic factors in adult granulosa cell tumor of the ovary Cancer 79 1997 1951 1955
5. J. Brown, A.K. Sood, M.T. Deavers, L. Milojevic, and D.M. Gershenson Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 113 2009 86 90
6. G. Mangili, C. Sigismondi, L. Frigerio, M. Candiani, A. Savarese, and G. Giorda et al. Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study Gynecol Oncol 130 2013 38 42
7. H. Fox, K. Agrawal, and F.A. Langley A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis Cancer 35 1975 231 241
8. R.E. Lappohn, H.G. Burger, J. Bouma, M. Bangah, and M. Krans Inhibin as a marker for granulosa cell tumor Acta Obstet Gynecol Scand Suppl 155 1992 61 65
9. R.A. Rey, C. Lhomme, I. Marcillac, N. Lahlou, P. Duvillard, and N. Josso et al. Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol Am J Obstet Gynecol 174 1996 958 965
10. A. Amsterdam, and N. Selvaraj Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes Endocr Rev 18 1997 435 461
11. R. Rosario, M. Wilson, W.T. Cheng, K. Payne, P.A. Cohen, and P. Fong et al. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression Gynecol Oncol 131 2013 325 329
12. J.F. Hines, M.A. Khalifa, J.L. Moore, K.P. Fine, J.M. Lage, and W.A. Barnes Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature Gynecol Oncol 60 1996 484 488
13. L.A. Baldwin, B. Huang, R.W. Miller, T. Tucker, S.T. Goodrich, and I. Podzielinski et al. Ten-year relative survival for epithelial ovarian cancer Obstet Gynecol 120 2012 612 618
14. D. Pectasides, E. Pectasides, and A. Psyrri Granulosa cell tumor of the ovary Cancer Treat Rev 34 2008 1 12
15. S. Jamieson, and P.J. Fuller Molecular pathogenesis of granulosa cell tumors of the ovary Endocr Rev 33 2012 109 144
16. N.H. Uhlenhaut, S. Jakob, K. Anlag, T. Eisenberger, R. Sekido, and J. Kress et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation Cell 139 2009 1130 1142
17. D. Weigel, G. Jurgens, F. Kuttner, E. Seifert, and H. Jackle The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo Cell 57 1989 645 658
18. C. Eozenou, A.V. Carvalho, N. Forde, C. Giraud-Delville, L. Gall, and P. Lonergan et al. FOXL2 is regulated during the bovine estrous cycle and its expression in the endometrium is independent of conceptus-derived interferon tau Biol Reprod 87 2012 32
19. J. Cocquet, E. De Baere, M. Gareil, M. Pannetier, X. Xia, and M. Fellous et al. Structure, evolution and expression of the FOXL2 transcription unit Cytogenet Genome Res 101 2003 206 211
20. J. Cocquet, E. Pailhoux, F. Jaubert, N. Servel, X. Xia, and M. Pannetier et al. Evolution and expression of FOXL2 J Med Genet 39 2002 916 921
21. L. Crisponi, M. Deiana, A. Loi, F. Chiappe, M. Uda, and P. Amati et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome Nat Genet 27 2001 159 166
22. J.E. Garcia-Ortiz, E. Pelosi, S. Omari, T. Nedorezov, Y. Piao, and J. Karmazin et al. Foxl2 functions in sex determination and histogenesis throughout mouse ovary development BMC Dev Biol 9 2009 36
23. C. Ottolenghi, S. Omari, J.E. Garcia-Ortiz, M. Uda, L. Crisponi, and A. Forabosco et al. Foxl2 is required for commitment to ovary differentiation Hum Mol Genet 14 2005 2053 2062
24. K. Duffin, R.A. Bayne, A.J. Childs, C. Collins, and R.A. Anderson The forkhead transcription factor FOXL2 is expressed in somatic cells of the human ovary prior to follicle formation Mol Hum Reprod 15 2009 771 777
25. D. Schmidt, C.E. Ovitt, K. Anlag, S. Fehsenfeld, L. Gredsted, and A.C. Treier et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance Development 131 2004 933 942
26. M. Uda, C. Ottolenghi, L. Crisponi, J.E. Garcia, M. Deiana, and W. Kimber et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development Hum Mol Genet 13 2004 1171 1181
27. L. Crisponi, M. Uda, M. Deiana, A. Loi, R. Nagaraja, and F. Chiappe et al. FOXL2 inactivation by a translocation 171 kb away: analysis of 500 kb of chromosome 3 for candidate long-range regulatory sequences Genomics 83 2004 757 764
28. D. Beysen, J. Vandesompele, L. Messiaen, A. De Paepe, and E. De Baere The human FOXL2 mutation database Hum Mutat 24 2004 189 193
29. S.E. Harris, A.L. Chand, I.M. Winship, K. Gersak, K. Aittomaki, and A.N. Shelling Identification of novel mutations in FOXL2 associated with premature ovarian failure Mol Hum Reprod 8 2002 729 733
30. S.P. Shah, M. Kobel, J. Senz, R.D. Morin, B.A. Clarke, and K.C. Wiegand et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary N Engl J Med 360 2009 2719 2729
31. S. Jamieson, R. Butzow, N. Andersson, M. Alexiadis, L. Unkila-Kallio, and M. Heikinheimo et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary Mod Pathol 23 2010 1477 1485
32. M.S. Kim, S.Y. Hur, N.J. Yoo, and S.H. Lee Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers J Pathol 221 2010 147 152
33. T. Kim, C.O. Sung, S.Y. Song, D.S. Bae, and Y.L. Choi FOXL2 mutation in granulosa-cell tumours of the ovary Histopathology 56 2010 408 410
34. E. D'Angelo, A. Mozos, D. Nakayama, I. Espinosa, L. Catasus, and J. Munoz et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary Mod Pathol 24 2011 1360 1367
35. K.B. Geiersbach, E.A. Jarboe, M.S. Jahromi, C.L. Baker, C.N. Paxton, and S.R. Tripp et al. FOXL2 mutation and large-scale genomic imbalances in adult granulosa cell tumors of the ovary Cancer Genet 204 2011 596 602
36. J.F. Lima, L. Jin, A.R. de Araujo, M.R. Erikson-Johnson, A.M. Oliveira, and T.J. Sebo et al. FOXL2 mutations in granulosa cell tumors occurring in males Arch Pathol Lab Med 136 2012 825 828
37. K.A. Schrader, B. Gorbatcheva, J. Senz, A. Heravi-Moussavi, N. Melnyk, and C. Salamanca et al. The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors PLoS One 4 2009 e7988
38. O. Hes, T. Vanecek, F. Petersson, P. Grossmann, M. Hora, and D.M. Perez Montiel et al. Mutational analysis (c.402C>G) of the FOXL2 gene and immunohistochemical expression of the FOXL2 protein in testicular adult type granulosa cell tumors and incompletely differentiated sex cord stromal tumors Appl Immunohistochem Mol Morphol 19 2011 347 351
39. S. Lee, T.H. Kim, M. Won, J.J. Ko, J. Rho, and K. Lee et al. Absence of a FOXL2 mutation (402C→G) in the blood of adult-type granulosa cell tumor patients possessing the FOXL2 mutation Int J Gynecol Cancer 20 2010 1341 1343
40. L.M. Roth Recent advances in the pathology and classification of ovarian sex cord-stromal tumours Int J Gynecol Pathol 25 2006 199 215
41. M. Kobel, C.B. Gilks, and D.G. Huntsman Adult-type granulosa cell tumors and FOXL2 mutation Cancer Res 69 2009 9160 9162
42. S. Tran, P. Lamba, Y. Wang, and D.J. Bernard SMAD and FOXL2 synergistically regulate murine FSHbeta transcription via a conserved proximal promoter element Mol Endocrinol 25 2011 1170 1183
43. A.L. Blount, K. Schmidt, N.J. Justice, W.W. Vale, W.H. Fischer, and L.M. Bilezikjian FoxL2 and Smad3 coordinately regulate follistatin gene transcription J Biol Chem 284 2009 7631 7645
44. P.S. Corpuz, L.L. Lindaman, P.L. Mellon, and D. Coss FoxL2 Is required for activin induction of the mouse and human follicle-stimulating hormone beta-subunit genes Mol Endocrinol 24 2010 1037 1051
45. A.N. Blackler, W.W. Vale, and L.M. Bilezikjian Understanding the mechanism and partnership of FoxL2 and Smad3 actions in pituitary gonadotropes Endocr Rev 2012
46. B.A. Benayoun, S. Caburet, A. Dipietromaria, A. Georges, B. D'Haene, and P.J. Pandaranayaka et al. Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G) PLoS One 5 2010 e8789
47. M. Marongiu, M. Deiana, A. Meloni, L. Marcia, A. Puddu, and A. Cao et al. The forkhead transcription factor Foxl2 is sumoylated in both human and mouse: sumoylation affects its stability, localization, and activity PLoS One 5 2010 e9477
48. M.D. Pisarska, F.T. Kuo, I.K. Bentsi-Barnes, S. Khan, and G.M. Barlow LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity Am J Physiol Endocrinol Metab 299 2010 E101 E109
49. B.A. Benayoun, A.B. Georges, D. L'Hote, N. Andersson, A. Dipietromaria, and A.L. Todeschini et al. Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase Hum Mol Genet 20 2011 1673 1686
50. R. Rosario, H. Araki, C.G. Print, and A.N. Shelling The transcriptional targets of mutant FOXL2 in granulosa cell tumours PLoS One 7 2012 e46270
51. B.A. Benayoun, M. Anttonen, D. L'Hote, M. Bailly-Bechet, N. Andersson, and M. Heikinheimo et al. Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation Oncogene 32 2013 2739 2746
52. N.I. Fleming, K.C. Knower, K.A. Lazarus, P.J. Fuller, E.R. Simpson, and C.D. Clyne Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter PLoS One 5 2010 e14389
53. J.H. Kim, S. Yoon, M. Park, H.O. Park, J.J. Ko, and K. Lee et al. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W) Oncogene 30 2011 1653 1663
54. D. L'Hote, A. Georges, A.L. Todeschini, J.H. Kim, B.A. Benayoun, and J. Bae et al. Discovery of novel protein partners of the transcription factor FOXL2 provides insights into its physiopathological roles Hum Mol Genet 21 2012 3264 3274
55. J.C. Cheng, C. Klausen, and P.C. Leung Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors PLoS One 8 2013 e55099
56. B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz, and K.W. Kinzler Cancer genome landscapes Science 339 2013 1546 1558
57. R. Gershon, S. Aviel-Ronen, J. Korach, V. Daniel-Carmi, C. Avivi, and D. Bar-Ilan et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors Gynecol Oncol 122 2011 580 584
58. R.H. Watson, W.J. Roy Jr., M. Davis, A. Hitchcock, and I.G. Campbell Loss of heterozygosity at the alpha-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors Gynecol Oncol 65 1997 387 390
59. N. Kalfa, M. Fellous, B. Boizet-Bonhoure, C. Patte, P. Duvillard, and C. Pienkowski et al. Aberrant expression of ovary determining gene FOXL2 in the testis and juvenile granulosa cell tumor in children J Urol 180 2008 1810 1813
60. N. Kalfa, P. Philibert, C. Patte, A. Ecochard, P. Duvillard, and P. Baldet et al. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children Fertil Steril 87 2007 896 901
61. D. Beysen, A. De Paepe, and E. De Baere FOXL2 mutations and genomic rearrangements in BPES Hum Mutat 30 2009 158 169
62. I.W. Chong, M.Y. Chang, H.C. Chang, Y.P. Yu, C.C. Sheu, and J.R. Tsai et al. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer Oncol Rep 16 2006 981 988
63. K.M. Carlson, S. Dou, D. Chi, N. Scavarda, K. Toshima, and C.E. Jackson et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B Proc Natl Acad Sci U S A 91 1994 1579 1583
64. H.Y. Fan, and J.S. Richards Minireview: physiological and pathological actions of RAS in the ovary Mol Endocrinol 24 2009 286 298
65. T.J. Giordano, R. Kuick, D.G. Thomas, D.E. Misek, M. Vinco, and D. Sanders et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis Oncogene 24 2005 6646 6656
66. C. James, V. Ugo, J.P. Le Couedic, J. Staerk, F. Delhommeau, and C. Lacout et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
67. I.R. Watson, K. Takahashi, P.A. Futreal, and L. Chin Emerging patterns of somatic mutations in cancer Nat Rev Genet 14 2013 703 718
68. S. Kommoss, M.S. Anglesio, R. Mackenzie, W. Yang, J. Senz, and J. Ho et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines Mod Pathol 26 2013 860 867
69. A. Sunters, P.A. Madureira, K.M. Pomeranz, M. Aubert, J.J. Brosens, and S.J. Cook et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt Cancer Res 66 2006 212 220
70. Z. Zeng, I.J. Samudio, W. Zhang, Z. Estrov, H. Pelicano, and D. Harris et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia Cancer Res 66 2006 3737 3746
71. A. Essafi, S. Fernandez de Mattos, Y.A. Hassen, I. Soeiro, G.J. Mufti, and N.S. Thomas et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells Oncogene 24 2005 2317 2329